Centro Médico Teknon
Centro Médico Teknon
Spain, Barcelona
Jaume Capdevila
26 years of experience
accreditations :
Clinic is certified :
Immunotherapy in Spain typically costs from $4,000. The final price depends on the drug protocol, cancer type, and number of treatment cycles required. Patients save around 86% compared to the US, where the average cost is $28,500. Most Spanish clinics bundle specialist consultations, diagnostic tests, and medication administration into the total price.
Bookimed Expert Insight: Spain offers a unique high-value entry point for experimental oncology. Patients at Quironsalud Madrid may access cutting-edge immunodrugs for free via clinical trials. Specialized centers like SJD Barcelona Children’s Hospital use in-house molecular labs to refine treatment. This reduces waste on ineffective drugs. Clinics like Centro Médico Teknon provide JCI-accredited care while hosting world-renowned specialists at competitive European rates.
| Turkey | Austria | Spain | |
| Immunotherapy | from $3,000 | ≈ $9,000 | from $4,000 |
| Sarcoma Immunotherapy | from $8,900 | ≈ $18,000 | from $6,200 |
| Immunotherapy for prostate cancer | from $8,000 | ≈ $9,500 | from $6,200 |
| Immunotherapy for lung cancer | from $8,000 | ≈ $30,000 | from $5,000 |
| Immunotherapy for kidney cancer | from $8,000 | ≈ $28,000 | from $2,200 |
No hidden fees – just official clinic prices. Pay at the clinic for Immunotherapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy journey.
Dr. Jaume Capdevila is a medical oncologist at Teknon Medical Center in Barcelona. He specializes in treating cancers of the digestive and endocrine systems. Dr. Capdevila is a co-founder of the Spanish Task Force Group for Orphan and Infrequent Tumors.
Dr. Graupera heads the Hematology Oncology Department at Sant Joan De Déu – one of Europe's top children's hospitals. His research focuses on pediatric cancer treatments.
Dr. Carlos Pollán leads the robotic head and neck surgery program at Centro Médico Teknon. He is a specialist in endoscopic skull base surgery and oncology. Dr. Pollán has performed over 430 operations. He uses the Da Vinci system for precise, minimally invasive procedures. Dr. Pollán trained at the University of Pittsburgh and the University Hospital of Pisa.
The doctor is a highly qualified medical oncologist specializing in breast cancer across all clinical stages, including curative and palliative care. With a medical degree from the Pontificia Universidad Católica del Ecuador and a five-year residency at Hospital de la Santa Creu i Sant Pau, the doctor holds a Master's Degree in Medical Oncology from the Spanish Society of Medical Oncology (SEOM).
Currently practicing at the International Breast Cancer Center (IBCC) and IOB Institute of Oncology Barcelona, the doctor has extensive experience in Phase I clinical trials and research. Clinical expertise extends to neuroendocrine tumors, gynecological cancers, and immunotherapy for non-small cell lung cancer. The doctor is an active member of SEOM and ESMO.
Written by Kateryna Zamkovska
When considering Immunotherapy, it’s important to understand the different techniques and which is best suited for you. Here’s a concise comparison of popular options:
Keytruda, a form of immune-based therapy, leverages the body's immune system to target and destroy cancer cells using monoclonal antibodies.
Spain provides advanced immunotherapy options including checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Leading centers like Centro Médico Teknon and Clínica Universidad de Navarra utilize biomarker-driven precision oncology to treat lung, breast, and hematologic cancers with drugs like Keytruda and Opdivo.
Bookimed Expert Insight: Spain stands out globally for institutional clinical trials. At Quironsalud Madrid, patients may qualify for free access to next-generation immunotherapy through active trials. Always confirm if your specific cancer markers, like PD-L1 or MSI, have been tested. These results often dictate which high-cost drugs clinics will approve for your case.
Patient Consensus: Patients recommend confirming the exact drug protocol and biomarker requirements early. Many highlight the importance of reporting immune-related side effects, such as fatigue or rashes, immediately to the clinical team.
Spain features internationally accredited institutions specialized in cutting-edge oncological care. Top hospitals for cancer immunotherapy include Clinica Universidad de Navarra, Centro Medico Teknon, and MD Anderson Cancer Center Madrid. These centers offer advanced checkpoint inhibitors, personalized biomarker matching, and access to international clinical trials.
Bookimed Expert Insight: Spain's oncology landscape is unique because private centers like Clinica Universidad de Navarra often lead in JCI certifications. However, our data shows institutional clusters in Madrid and Barcelona provide the best access to multidisciplinary tumor boards. For complex immunotherapy, look for clinics like Quironsalud Madrid that host over 20+ active Phase II and III trials.
Patient Consensus: Patients prioritize clinics with in-house molecular labs for PD-L1 testing and tumor board reviews. Many suggest visiting these reference centers in Madrid or Barcelona specifically for treatment planning before starting regimens.
International patients can access immunotherapy clinical trials in Spain through private centers and research hubs, though eligibility is determined on a case-by-case basis. Spain leads European oncology research, with clinics like Quironsalud Madrid offering free treatment for eligible participants in active Phase I-III studies.
Bookimed Expert Insight: While major centers like Quironsalud Barcelona and Teknon Medical Center serve thousands of international patients, trial success often depends on specialized units. For instance, Dr. Francesc Bosch at Quironsalud Barcelona currently manages over 80 Phase I-III trials. Patients should target institutions where principal investigators have a high volume of registration-enabling trials, as these clinics often have the most robust infrastructure for international enrollment and safety reporting.
Patient Consensus: Success depends on having a complete medical dossier ready, including translated pathology reports and specific biomarker panels like PD-L1 or MSI. Many find that early-phase trials are logistically difficult due to frequent monitoring, making later-phase studies more practical for those traveling from abroad.